Claims
- 1. A method for maintaining the suitability for transfusion purposes of platelets which may contain pathogens during a pathogen reduction process comprising the steps of:
adding a pathogen reducing compound to the platelets; adding to the platelets and pathogen reducing compound at least one platelet activation inhibitor additive; and exposing the platelets and pathogen reducing compound and at least one platelet activation inhibitor additive to light of a sufficient wavelength to reduce any pathogens contained in the platelets.
- 2. The method of claim 1 wherein the step of adding to the platelets and pathogen reducing compound at least one platelet activation inhibitor additive occurs prior to the exposing step.
- 3. The method of claim 1 wherein the step of adding to the platelets and pathogen reducing compound at least one platelet activation inhibitor additive occurs subsequent to the exposing step.
- 4. The method of claim 1 wherein the at least one platelet activation inhibitor additive is an adenylate cyclase stimulator in an amount effective to increase the production of adenosine 3′, 5′ cyclic phosphate in the platelets.
- 5. The method of claim 1 wherein the adenylate cyclase stimulator is selected from the group consisting of PGE1 and forskolin.
- 6. The method of claim 5 wherein PGE1 is added at a final concentration of between about 100 nM and 500 nM.
- 7. The method of claim 6 wherein PGE1 is added at a final concentration of 150 nM.
- 8. The method of claim 5 wherein forskolin is added at a final concentration of between about 1 μM and 100 μM.
- 9. The method of claim 8 wherein forskolin is added at a final concentration of about 3 μM.
- 10. The method of claim 1 wherein the at least one platelet activation inhibitor additive is a phosphodiesterase inhibitor in an amount effective to reduce the degradation of cAMP in the platelets.
- 11. The method of claim 10 wherein the phosphodiesterase inhibitor is a methylxanthine.
- 12. The method of claim 10 wherein the phosphodiesterase inhibitor is selected from the group consisting of xanthine, theophylline, caffeine, theobromine, aminophylline, oxtriphylline, dyphylline, pentoxifylline, isobutulmethylxanthine, dipyramole, and papaverine.
- 13. The method of claim 11 wherein the methylxanthine is theophylline added at a final concentration of between about 0.90 mM and 2.2 mM.
- 14. The method of claim 13 wherein the theophylline is added at a final concentration of about 0.95 mM.
- 15. The method of claim 11 wherein the methylxanthine is caffeine added at a final concentration of between about 0.9 mM and 2.2 mM.
- 16. The method of claim 15 wherein the caffeine is added at a final concentration of about 0.95 mM.
- 17. The method of claim 1 wherein the step of adding to the platelets and pathogen reducing compound at least one platelet activation inhibitor additive further comprises adding a second platelet activation inhibitor additive.
- 18. The method of claim 17 wherein the at least one platelet activation inhibitor additive comprises an adenylate cyclase stimulator and the second platelet activation inhibitor additive comprises a phosphodiesterase inhibitor.
- 19. The method of claim 1 wherein the step of adding to the platelets and pathogen reducing compound at least one platelet activation inhibitor additive further comprises adding a glycolytic inhibitor.
- 20. The method of claim 19 wherein the glycolytic inhibitor is 2-deoxy-D-glucose.
- 21. The method of claim 1 wherein the step of adding to the platelets and pathogen reducing compound at least one platelet activation inhibitor additive further comprises adding at least one quencher.
- 22. The method of claim 21 wherein the quencher is selected from the group consisting of adenine, histidine, cysteine, tyrosine, tryptophan, ascorbate, N-acetyl-L-cysteine, propyl gallate, glutathione, mercaptopropionylglycine, dithiothreotol, nicotinamide, BHT, BHA, lysine, serine, methionine, glucose, mannitol, vitamin E, trolox, alpha-tocopheral acetate and various derivatives, glycerol, and mixtures thereof.
- 23. The method of claim 1 wherein the pathogen reducing compound comprises a photosensitizer.
- 24. The method of claim 23 wherein the photosensitizer is an endogenous photosensitizer.
- 25. The method of claim 24 wherein the endogenous photosensitizer is riboflavin.
- 26. A storage solution for maintaining the cell quality of pathogen reduced platelets during storage comprising:
a pathogen reducing compound; and at least one platelet activation inhibitor additive.
- 27. The storage solution of claim 26 wherein the storage solution may also be used as a pathogen reduction solution.
- 28. The storage solution of claim 26 wherein the at least one platelet activation inhibitor comprises an adenylate cyclase stimulator in an amount effective to increase the production of adenosine 3′, 5′ cyclic phosphate in the platelets.
- 29. The storage solution of claim 28 wherein the adenylate cyclase stimulator is selected from the group consisting of PGE1 and forskolin.
- 30. The storage solution of claim 29 wherein PGE1 is added at a final concentration of between about 100 nM and 500 nM.
- 31. The storage solution of claim 30 wherein PGE1 is added at a final concentration of 150 nM.
- 32. The storage solution of claim 29 wherein forskolin is added at a final concentration of between about 1 μM and 100 μM.
- 33. The storage solution of claim 32 wherein forskolin is added at a final concentration of about 3 μM.
- 34. The storage solution of claim 26 wherein the at least one platelet activation inhibitor additive is a phosphodiesterase inhibitor in an amount effective to reduce the degradation of cAMP in the platelets.
- 35. The storage solution of claim 34 wherein the phosphodiesterase inhibitor is a methylxanthine.
- 36. The storage solution of claim 34 wherein the phosphodiesterase inhibitor is selected from the group consisting of xanthine, theophylline, caffeine, theobromine, aminophylline, oxtriphylline, dyphylline, pentoxifylline, isobutulmethylxanthine, dipyramole, and papaverine.
- 37. The storage solution of claim 35 wherein the methylxanthine is theophylline added at a final concentration of between about 0.90 mM and 2.2 mM.
- 38. The storage solution of claim 37 wherein the theophylline is added at a final concentration of about 0.95 mM.
- 39. The storage solution of claim 35 wherein the methylxanthine is caffeine added at a final concentration of between about 0.90 mM and 2.2 mM.
- 40. The storage solution of claim 39 wherein the caffeine is added at a final concentration of about 0.95 mM.
- 41. The storage solution of claim 26 wherein the at least one platelet activation inhibitor additive further comprises a second platelet activation inhibitor additive.
- 42. The storage solution of claim 41 wherein the at least one platelet activation inhibitor additive comprises an adenylate cyclase stimulator and the second platelet activation inhibitor additive comprises a phosphodiesterase inhibitor.
- 43. The storage solution of claim 26 further comprising a glycolytic inhibitor.
- 44. The storage solution of claim 43 wherein the glycolytic inhibitor is 2-deoxy-D-glucose.
- 45. The storage solution of claim 26 further comprising at least one quencher.
- 46. The storage solution of claim 45 wherein the quencher is selected from the group consisting of adenine, histidine, cysteine, tyrosine, tryptophan, ascorbate, N-acetyl-L-cysteine, propyl gallate, glutathione, mercaptopropionylglycine, dithiothreotol, nicotinamide, BHT, BHA, lysine, serine, methionine, glucose, mannitol, vitamin E, trolox, alpha-tocopheral acetate and various derivatives, glycerol, and mixtures thereof.
- 47. The storage solution of claim 26 wherein the pathogen reducing compound comprises a photosensitizer.
- 48. The storage solution of claim 47 wherein the photosensitizer is an endogenous photosensitizer.
- 49. The storage solution of claim 48 wherein the endogenous photosensitizer is riboflavin.
- 50. The storage solution of claim 26 further comprising a solvent.
- 51. The storage solution of claim 50 wherein the solvent is selected from the group consisting of PSS1, PSS2, PSS3, PSS4, PSS5, PSS6, PSS7, PSS8 and PSS9.
- 52. The storage solution of claim 50 wherein the solvent is selected from the group consisting of saline and water.
- 53. A fluid for transfusing into a recipient comprising:
platelets; a pathogen reduction compound; and one or more platelet activation inhibitor additives.
CROSS REFERENCE To RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional patent application No. 60/375,670 filed Apr. 26, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60375670 |
Apr 2002 |
US |